Enrofloxacin 50 mg/ml Solution for Injection
Country: Greece
Language: English
Source: HMA (Heads of Medicines Agencies)
Summary of Product characteristics
(SPC)
21-08-2013
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
enrofloxacin 50 mg/ml
Available from:
Pfizer Limited
ATC code:
QM01AC06
Pharmaceutical form:
Solution for injection
Therapeutic group:
meloxicam
Therapeutic area:
Cats, Cattle, Dogs, Pigs
Authorization date:
2011-12-21
Summary of Product characteristics
Issued: February 2012
AN: 01748/2010
Page 1 of 8
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Reneval 50 mg/ml Solution for Injection for cattle, pigs, dogs and cats.
Reneval (DK)
Reneval vet. 50 mg/ml Solution for Injection for cattle, pigs, dogs and cats. (FI,
SE)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml of solution contains:
Active substance
Enrofloxacin
50.0 mg
Excipients
n-Butanol
30.0 mg
For full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear light yellow solution free from particulate matter.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle, Pigs, Dogs and Cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Cattle:
Diseases of the respiratory and alimentary tract of bacterial or mycoplasmal
origin (e.g. _pasteurellosis, mycoplasmosis, coli-bacillosis, coli-septicaemia and _
salmonellosis) and secondary bacterial infections subsequent to viral
conditions (e.g. viral pneumonia), where clinical experience, supported where
possible by sensitivity testing of the causal organism, indicates enrofloxacin as
the drug of choice.
Issued: February 2012
AN: 01748/2010
Page 2 of 8
Pigs:
Diseases of the respiratory and alimentary tract of bacterial or mycoplasmal
origin (e.g. _pasteurellosis, actinobacillosis, mycoplasmosis, coli-bacillosis, coli-_
_septicaemia and _salmonellosis) and multifactorial diseases such as atrophic
rhinitis and enzootic pneumonia, where clinical experience, supported where
possible by sensitivity testing of the causal orga
Read the complete document
